In the pairwise comparison between the two nivolumab combination therapies, nivolumab plus ipilimumab increased the cost by $891.12 with the augments of 0.07 QALYs against nivolumab plus chemotherapy for PD-L1-positive advanced ESCC patients, and the ICER ($12,157.66/QALY) was lower than the WTP threshold. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.